Compare · ABT vs GYRE
ABT vs GYRE
Side-by-side comparison of Abbott Laboratories (ABT) and Gyre Therapeutics Inc. (GYRE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and GYRE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $152.90B, about 271.2x GYRE ($563.7M).
- Over the past year, ABT is down 34.3% and GYRE is down 23.7% - GYRE leads by 10.6 points.
- GYRE has been more active in the news (8 items in the past 4 weeks vs 4 for ABT).
- ABT has more recent analyst coverage (25 ratings vs 3 for GYRE).
- Company
- Abbott Laboratories
- Gyre Therapeutics Inc.
- Price
- $87.73+2.52%
- $5.82-1.27%
- Market cap
- $152.90B
- $563.7M
- 1M return
- -3.20%
- -23.92%
- 1Y return
- -34.34%
- -23.72%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2006
- News (4w)
- 4
- 8
- Recent ratings
- 25
- 3
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
- New insider Conroy Kevin T claimed ownership of 131,451 units of Common shares without par value (SEC Form 3)
- Director Stratton John G was granted 2,286 units of Common shares without par value, increasing direct ownership by 12% to 21,319 units (SEC Form 4)
Latest GYRE
- Chief Operating Officer Ye Weiguo exercised 7,500 shares at a strike of $0.75 and sold $45,680 worth of shares (7,500 units at $6.09) (SEC Form 4)
- Chief Operating Officer Ye Weiguo exercised 22,220 shares at a strike of $0.75 and sold $136,653 worth of shares (22,220 units at $6.15) (SEC Form 4)
- SEC Form 4 filed by Director Zhang Ping
- Chief Operating Officer Ye Weiguo exercised 9,320 shares at a strike of $0.75 and sold $59,418 worth of shares (9,320 units at $6.38) (SEC Form 4)
- Chief Operating Officer Ye Weiguo exercised 28,680 shares at a strike of $0.75 and sold $194,773 worth of shares (28,680 units at $6.79) (SEC Form 4)
- Gyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Gyre Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment
- SEC Form 10-Q filed by Gyre Therapeutics Inc.
- Chief Executive Officer Luo Ying sold $82,927 worth of shares (10,315 units at $8.04) as part of a pre-agreed trading plan (SEC Form 4)